-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:Axon第一季度营收达8.07亿美元(同比增长34%),超出市场预期3.5%,连续第九个季度实现30%以上的增长。调整后每股收益为1.61美元,同比增长9.5%,略高于预期,但由于持续的利润率压力,每股收益增速相对于营收增速有所放缓。业绩进一步印证了Axon的整合生态系统战略在多个垂直领域均获得了客户的认可,软件与服务(同比增长35%至3.55亿美元)和互联设备(同比增长33%至4.53亿美元)两大业务板块表现均衡强劲。管理层维持了2026年全年业绩预期,即EBITDA利润率25.5%,营收增长27%-30%。平台解决方案业务同比增长95%至1.11亿美元,其中反无人机系统业务在收购Dedrone后同比增长超过300%,人工智能时代计划产品业务同比增长超过700%。年度经常性收入达到15亿美元(同比增长35%),净收入留存率达125%,而未来合同订单同比增长44%至143亿美元,为实现2028年60亿美元的宏伟收入目标提供了有力支撑,并确保了强劲的收入前景。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.